Effects of Transcranial Pulse Stimulation on ASD

Autism Spectrum Disorder Clinical Trial

Official title:

Evaluating the Efficacy of Transcranial Pulse Stimulation (TPS) on Individuals With Autism Spectrum Disorder (ASD)- A Double-blinded, Randomized, Sham-controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05408793
• Other study ID #: HongKongPU_HSEARS20220228005
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2022
• Est. completion date: August 31, 2024

Study information

• Verified date: May 2022
• Source: The Hong Kong Polytechnic University
• Contact: Teris Cheung, PhD
• Phone: 852 34003912
• Email: teris.cheung[@]polyu.edu.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy and tolerability of TPS on young adolescents with ASD. Methods: This is a two-armed, randomized, double-blinded, sham-controlled trial. Sampling: A total number of 36 subjects, aged between 12 to 17, diagnosed with ASD, will be recruited. Individuals with a Childhood of Autism Rating Scale (CARS) score ≤ 30 (i.e., no ASD) will be excluded. Recruitment: Subjects will be recruited from the community. Block randomization will be performed to allocate subjects to either the verum TPS group or the sham TPS group on a 1: 1 ratio. Interventionists and subjects will be blinded in the randomization process. Intervention: Intervention: Six 30-minures TPS sessions will be delivered to the verum TPS group (800 pulse in each session, total: 4800 pulse) in consecutive two weeks. The treatment brain region is targeted at the right temporoparietal junction (rTPJ). The sham- controlled group will be given 6 sham TPS sessions. Data collection: All participants are required to undertake pre-and-post fMRI and resting-MRI before the TPS procedures. Outcomes: Primary outcome of this study is CARS, and secondary outcomes include Autism Spectrum Quotient (AQ), Australian scale for Asperger's syndrome (ASAS), Social Responsive Scale (SRS), Faux Pas Recognition Test (FPRT), Stroop test, working memory, Clinical global impression - severity and improvement scale (CGI-S and CGI -I) and neuroimaging. All outcome measures will be assessed at baseline, two weeks immediately after intervention and at 1-month and 3-months follow-up.

Description:

Primary objective: 1. Participants in the verum TPS group will have a significant reduction in CARS score at posttreatment compared with the sham TPS group. Secondary objectives: 2. Participants in the verum TPS group will have significant improvement in Autism Spectrum Quotient (AQ), compared with the sham TPS group. 3. Participants in the verum TPS group will have significant improvement in the Social Responsiveness Scale (SRS), compared with the sham TPS group. 4. Participants in the verum TPS group will have significant improvement in Faux Pas Recognition Test, compared with the sham TPS group. 5. Participants in the verum TPS group will have significant improvement in Stroop test, compared with the sham TPS group. 6. Participants in the verum TPS group will have significant improvement in Clinical global impression - severity and improvement scale (CGI-S and CGI -I) compared with the sham TPS group. 7. Participants in the verum TPS group will have significant brain function connectivity at posttreatment fMRI and resting-state MRI compared to the sham TPS group. Sample size Based on an RCT with similar design, the estimated effect size of rTMS is 0.5. By adapting an ANOVA 2x2 repeated measures with 95% significance and a power of 0.8, a sample size of 36 will be required in total (18 subjects per group). Research plan and Methodology Methods Trial Design: In this study, the investigators will use a double-blind randomized controlled trial design with two-armed repeated measures. The trial design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement. In this two-armed design, investigators will use TPS as an intervention group and a waitlist control group. A sham-control group is appropriate for comparing the effect of the TPS on the intervention group to that of those not receiving the TPS treatment at the same timepoints Both groups will be measured at baseline (T1), immediately after the intervention (T2), at the 1-month (T3) and 3-month follow-up (T4). Based on the previous studies, a 3-month follow-up is sufficient to assess the long-term sustainability of the TPS intervention. Intervention (Transcranial Pulse Stimulation) Purpose of the intervention: The key tenets of the TPS intervention is neuromodulation, i.e., using ultrasound-based brain stimulation techniques to modulate the human brain in a focal and targeted manner. Intervention dose: Each participant should have the pre-treatment MRI scan performed in the University Research Facility in Behavioural and Systems Neuroscience, PolyU prior coming to the first intervention session. All participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time. Participants will be followed up immediately after post-stimulation in Week 2, and at 1-month and 3- month period after the intervention. The investigators believe that a 2-week TPS intervention is sufficient enough to test the effects of TPS on autism symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: August 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

1. 12 -17 years of age

2. Chinese ethnicity

3. Diagnosis of Autistic Spectrum Disorder that meets the criteria of the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

4. No change in their management including medications or non-pharmacological intervention

5. Currently taking prescribed psychotropic medications for = 3 months

Exclusion Criteria:

1. A DSM-5 diagnosis other than ASD

2. Concomitant major medical or neurological conditions, such as significant global developmental delay, skull defect, abnormal mass or tumor, or epilepsy

3. A CARS score = 30 (i.e., no ASD)

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• High-functioning Autism

Intervention

Device:
• Transcranial Pulse Stimulation
A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.

Locations

Country	Name	City	State
Hong Kong	School of Nursing HongKongPolyU	HongKong

Sponsors (1)

Lead Sponsor	Collaborator
The Hong Kong Polytechnic University

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Autism severity	The Childhood Autism Rating Scale (CARS) is a 15-item behavioral rating scale developed to identify autism and examine its severity. Total scores range from a low of 15 to a high of 60; scores below 30 indicate that the individual is in the non-autistic range, scores between 30 and 36.5 indicate mild to moderate autism, and scores from 37 to 60 indicate severe autism.	Changes in CARS scores from baseline at 3 months
Secondary	Autistic traits	Autism Spectrum Quotient (AQ) - adolescent version is a quick and quantitative self-report instrument for assessing how many autistic traits any adult has. The minimum score on the AQ is 0 and the maximum 50.	Changes in AQ scores from baseline at 3 months
Secondary	Social deficits	The Social Responsiveness Scale (SRS) is an instrument measuring the continuum of autism symptom severity which is commonly used in children and adolescents between the ages of 4 and 18 years. Parents rate on each item on a 4-item Likert scale (0-4). The higher the scores, the more severe the social deficits.	Changes in SRS from baseline at 3 months
Secondary	Asperger's Syndrome	Australian scale for Asperger's syndrome (ASAS) is a scale used to screen the behaviours and abilities indicative of Asperger's Syndrome in subjects older than 6 years old. It has 25 item and can be rated by parents/teachers/professionals who know the child.	Changes in ASAS from baseline at 3 months
Secondary	Theory of Mind and Social Cognition	Faux Pas Recognition Test (FPRT) is a very common advanced test to measure the theory of mind and social cognition	Changes in FPRT from baseline at 3 months
Secondary	Executive Function	Stroop test is commonly used to assess the inhibition control component of executive function. It is testing the subject's ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute.	Changes in Stroop test from baseline at 3 months
Secondary	Working memory	Working Memory Test Battery (WMTB), which includes two verbal storage-only tasks (i.e. digital recall and word list recall), two complex memory span tasks (i.e. backward digit recall and counting recall), and two visuospatial storage tasks (block recall and variant- visual-pattern test).	Changes in WMTB from baseline at 3 months
Secondary	Clinical Global Impression	CGI-S is a 7-point clinician rating scale is based upon observed and reported symptoms, behaviour, and function in the past seven days. CGI-I is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.	Changes in WMTB from baseline at 3 months
Secondary	Neuroimaging	Participants will receive pre and post treatment MRI scan to measure any changes in structural and functional connectivity changes in the brain.	MRI will be assessed at baseline at immediately and 2 weeks after post-stimulation